{"meta":{"query_hash":"59afb3db9958","filters":{"venue":"PAGEPress (PAGEPress (Italy))"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/59afb3db9958","api":"https://metacan.xera.ac/api/v1/cohort?venue=PAGEPress+%28PAGEPress+%28Italy%29%29"},"results":[{"id":"W6981214836","doi":"","title":"DREAMM-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma, including subgroups with renal impairment and high-risk cytogenetics: Session: Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"PAGEPress (PAGEPress (Italy))","topic":"Radiation Effects in Electronics","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Discontinuation; Population; Multiple myeloma; Adverse effect; Renal function; Population study; Malignancy","score_opus":0.008847762985695338,"score_gpt":0.1884282021824785,"score_spread":0.17958043919678315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981214836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98057866,0.010520266,0.00069029396,0.001855032,0.00018537579,0.00041366837,0.0015066138,0.0001377672,0.0041123256],"genre_scores_gemma":[0.99136436,0.002656664,0.0010784534,0.00071062456,0.00016681754,0.00023585811,0.0018576632,0.0000101000005,0.0019194541],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99982375,0.00006408837,0.000018879016,0.00003593589,0.000034635654,0.000022725493],"domain_scores_gemma":[0.99978226,0.000044588425,0.000056247663,0.0000099293065,0.000021141794,0.00008589833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007776527,0.00027714728,0.0007845661,0.00013951803,0.00017174537,0.0003485785,0.00026515825,0.00027604654,0.0029766285],"category_scores_gemma":[0.00048644666,0.00011669067,0.0005761363,0.00014497168,0.00011083987,0.00030771873,0.00025605402,0.00071187597,0.0003782892],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17708993,0.0055173673,0.123190455,0.002587164,0.0023231774,0.00041943704,0.00038895197,0.0029721644,0.05353092,0.0004761705,0.043657918,0.5878464],"study_design_scores_gemma":[0.15543973,0.21967046,0.5180411,0.00066281925,0.0031855372,0.0040295776,0.0003025292,0.007586137,0.020004753,0.0010982543,0.0698733,0.00010586849],"about_ca_topic_score_codex":0.00043880474,"about_ca_topic_score_gemma":0.0019485423,"teacher_disagreement_score":0.0029766285,"about_ca_system_score_codex":0.00062314206,"about_ca_system_score_gemma":0.00053473085,"threshold_uncertainty_score":0.00995779},"labels":[],"label_agreement":null},{"id":"W6981310148","doi":"","title":"DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma: Session: Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"PAGEPress (PAGEPress (Italy))","topic":"Diverse Scientific and Economic Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Adverse effect; Multiple myeloma; Interim analysis; Safety profile; Clinical trial","score_opus":0.04391471674687396,"score_gpt":0.24967030587193023,"score_spread":0.20575558912505626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981310148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753738,0.007099416,0.0010180526,0.0015673365,0.0002683389,0.0033808104,0.005279819,0.00030656756,0.005705762],"genre_scores_gemma":[0.9784856,0.0023017875,0.0031026988,0.0011538963,0.00028030563,0.0028860338,0.005082104,0.00004028446,0.006667255],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995111,0.0002307515,0.0000434416,0.00007486876,0.000072549934,0.00006725551],"domain_scores_gemma":[0.99922454,0.00013216204,0.00018169542,0.00004101544,0.00007564599,0.00034498548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017054627,0.0008592412,0.0016338838,0.0002721087,0.00031917501,0.00062366703,0.00072331255,0.0009498264,0.006862049],"category_scores_gemma":[0.00095008337,0.00035901647,0.0015360013,0.00020949643,0.0002136226,0.0004478321,0.0004283099,0.0019364485,0.0012973036],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5788638,0.038252,0.027339976,0.0021231107,0.0038507169,0.00027890695,0.0002923717,0.0050904895,0.07234762,0.0002452066,0.02446517,0.24685062],"study_design_scores_gemma":[0.2282118,0.6581166,0.08020385,0.0001714117,0.0018892739,0.00053958624,0.00007305911,0.0032671755,0.01341317,0.00029862422,0.013750083,0.000065404325],"about_ca_topic_score_codex":0.0010025321,"about_ca_topic_score_gemma":0.002460727,"teacher_disagreement_score":0.006862049,"about_ca_system_score_codex":0.0011393771,"about_ca_system_score_gemma":0.0013236823,"threshold_uncertainty_score":0.022955835},"labels":[],"label_agreement":null}]}